GREENLAND MINES LTD Operating Cash Flow
GREENLAND MINES LTD (GRML) reported Operating Cash Flow of -$11.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-17
- GREENLAND MINES LTD net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$6.85M.
- GREENLAND MINES LTD net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$4.97M.
- GREENLAND MINES LTD net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$1.28M.
- GREENLAND MINES LTD net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$1.12M.
- GREENLAND MINES LTD net cash provided by (used in) operating activities for fiscal 2025 was -$5.89M.
- GREENLAND MINES LTD net cash provided by (used in) operating activities for fiscal 2024 was -$2.95M.
- GREENLAND MINES LTD net cash provided by (used in) operating activities for fiscal 2023 was -$446.92K.
- GREENLAND MINES LTD net cash provided by (used in) operating activities for fiscal 2022 was -$493.04K.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 10 month | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$6.85M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | -$11.83M 10-Q · filed 2026-08-17 | -$13.10M derived: sum of 3 quarters · filed 2026-08-17 | -$14.22M derived: sum of 4 quarters · filed 2026-08-17 | |||||
| 2026-03-31 | -$4.97M 10-Q/A · filed 2026-08-14 | -$6.25M derived: sum of 2 quarters · filed 2026-08-14 | -$7.37M derived: sum of 3 quarters · filed 2026-08-14 | -$9.31M derived: sum of 4 quarters · filed 2026-08-17 | |||||
| 2025-12-31 | -$1.28M derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | -$2.40M derived: sum of 2 quarters · filed 2026-08-14 | -$4.34M derived: sum of 3 quarters · filed 2026-08-17 | -$5.89M 10-K/A · filed 2026-08-14 | |||||
| 2025-09-30 | -$1.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$3.06M derived: sum of 2 quarters · filed 2026-08-17 | -$4.61M 10-Q · filed 2025-11-13 | -$5.55M derived: sum of 4 quarters · filed 2026-08-17 | |||||
| 2025-06-30 | -$1.94M derived: 10-Q 6 month − 10-Q/A 3 month · filed 2026-08-17 | -$3.49M 10-Q · filed 2026-08-17 | -$3.52M 10-Q · filed 2025-08-18 | -$4.44M derived: sum of 3 quarters · filed 2026-08-17 | -$5.51M derived: sum of 4 quarters · filed 2026-08-17 | ||||
| 2025-03-31 | -$1.55M 10-Q/A · filed 2026-08-14 | -$2.50M derived: sum of 2 quarters · filed 2026-08-14 | -$3.57M derived: sum of 3 quarters · filed 2026-08-14 | -$4.48M derived: sum of 4 quarters · filed 2026-08-14 | |||||
| 2024-12-31 | -$944.15K derived: 10-K/A 12 month − 10-Q 9 month · filed 2026-08-14 | -$2.02M derived: sum of 2 quarters · filed 2026-08-14 | -$2.92M derived: sum of 3 quarters · filed 2026-08-14 | -$2.95M 10-K/A · filed 2026-08-14 | |||||
| 2024-09-30 | -$1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$1.98M derived: sum of 2 quarters · filed 2025-11-13 | -$2.00M 10-Q · filed 2025-11-13 | -$2.20M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | -$907.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-18 | -$929.40K 10-Q · filed 2025-08-18 | -$1.13M derived: sum of 3 quarters · filed 2025-08-18 | -$1.11M derived: sum of 4 quarters · filed 2025-08-18 | |||||
| 2024-03-31 | -$21.98K 10-Q · filed 2025-05-15 | -$376.54K 10-Q · filed 2024-05-23 | -$221.49K derived: sum of 2 quarters · filed 2025-05-15 | -$203.46K derived: sum of 3 quarters · filed 2025-05-15 | -$95.92K derived: sum of 4 quarters · filed 2025-05-15 | ||||
| 2023-12-31 | -$199.51K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$181.49K derived: sum of 2 quarters · filed 2025-03-31 | -$73.94K derived: sum of 3 quarters · filed 2025-03-31 | -$446.92K 10-K · filed 2025-03-31 | -$1.26M 10-K · filed 2024-04-17 | ||||
| 2023-09-30 | $18.02K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-19 | $125.57K derived: sum of 2 quarters · filed 2024-11-19 | -$247.41K 10-Q · filed 2024-11-19 | -$1.01M 10-Q · filed 2023-11-17 | -$320.59K derived: sum of 4 quarters · filed 2024-11-19 | ||||
| 2023-06-30 | $107.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-19 | -$265.43K 10-Q · filed 2024-08-19 | -$886.47K 10-Q · filed 2023-08-21 | -$338.61K derived: sum of 3 quarters · filed 2024-08-19 | -$371.85K derived: sum of 4 quarters · filed 2024-08-19 | ||||
| 2023-03-31 | -$372.98K 10-Q · filed 2024-05-23 | -$446.16K derived: sum of 2 quarters · filed 2024-05-23 | -$479.40K derived: sum of 3 quarters · filed 2024-05-23 | -$872.31K derived: sum of 4 quarters · filed 2024-05-23 | |||||
| 2022-12-31 | -$73.18K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-17 | -$106.42K derived: sum of 2 quarters · filed 2024-04-17 | -$499.33K derived: sum of 3 quarters · filed 2024-04-17 | -$493.04K 10-K · filed 2024-04-17 | |||||
| 2022-09-30 | -$33.24K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-17 | -$426.15K derived: sum of 2 quarters · filed 2023-11-17 | -$419.86K 10-Q · filed 2023-11-17 | ||||||
| 2022-06-30 | -$392.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | -$386.62K 10-Q · filed 2023-08-21 | |||||||
| 2022-03-31 | $6.29K 10-Q · filed 2023-05-24 | ||||||||
| 2021-12-31 | $4.95K 10-K/A · filed 2023-10-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |